spacer
home > ebr > winter 2001 > periodic safety update reports help assure pharmacovigilance in an era of unprecedented change
PUBLICATIONS
European Biopharmaceutical Review

Periodic Safety Update Reports Help Assure Pharmacovigilance in an Era of Unprecedented Change

The demands that stakeholders are placing on drug safety units can only be met through a structured approach to radically improve effectiveness and efficiency. Periodic safety update reports (PSURs) are effective stimuli for proactive pharmacovigilance, but they need to be produced at an even rate and with guaranteed consistency in both format and content. As the volumes of safety data continue to increase, firms that accept the status quo will restrict the ability to deliver accurate and timely safety data to patients, physicians and agencies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Chris Holmes, Principal of Pharmaceuticals Europe, and Glen Potvin, Managing Consultant, at World Class International Chris Holmes became a Business Consultant for World Class International in 1993, and has successfully led and managed global projects to simplify, control and improve business processes. This has produced significant improvements in business performance and has created a stable infrastructure for international pharmaceutical clients. Chris has been responsible for developing the successful Business Process Transformation methodology within World Class International, and his current role is Principal of Pharmaceuticals Europe.

Glen Potvin is a Managing Consultant and is involved with pharmaceutical companies across the US and Europe. He has responsibility for projects in areas such as new product introduction, process transformation, supply chain management, activity-based cost management, continuous improvement facilitation, benchmarking, and customer satisfaction management.
spacer
Chris Holmes
spacer
spacer
spacer
Glen Potvin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

GSK Completes Acquisition of Sierra Oncology

London, UK, 1 July, 2022: GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Sierra Oncology, Inc. (Sierra Oncology), a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer. The acquisition was approved by Sierra Oncology's shareholders on 29 June 2022.
More info >>

White Papers

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

Phlexglobal Ltd

Looking at some of the challenges of traditional paper-based Trial Master Files (TMFs), and how they can be overcome with Phlexglobal's best in breed electronic TMF system, PhlexEview.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement